Stay updated on Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial
Sign up to get notified when there's something new on the Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial page.

Latest updates to the Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check26 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check62 days agoChange DetectedThe web page has been updated to reflect a new clinical trial involving nivolumab, ipilimumab, and panitumumab for treating unresectable refractory KRAS/NRAS/BRAF wild-type metastatic colorectal cancer, with a new principal investigator, Hanna K Sanoff, MD, and collaborators Amgen and Bristol-Myers Squibb.SummaryDifference48%
Stay in the know with updates to Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Panitumumab, Nivolumab, Ipilimumab in mCRC Clinical Trial page.